Confidence in Concept 2012 - Edinburgh
Lead Research Organisation:
University of Edinburgh
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Organisations
- University of Edinburgh (Lead Research Organisation)
- Edinburgh Instruments Ltd (Collaboration)
- Multiplicom N.V. (Collaboration)
- Sequenom (Collaboration)
- Mercia Technologies PLC (Collaboration)
- Waters Corporation (Collaboration)
- Arrotek Medical Limited (Collaboration)
- Aquila BioMedical (Collaboration)
- Seafield and Cullen Medical Group (Collaboration)
- DestiNA Genomics Ltd (Collaboration)
- Heriot-Watt University (Collaboration)
- Perkin Elmer (Collaboration)
- Axis-Shield (Collaboration)
- Platts & Nisbett Ltd (Collaboration)
People |
ORCID iD |
| Jonathan Seckl (Principal Investigator) |
Publications
Antoine DJ
(2017)
Transformative biomarkers for drug-induced liver injury: are we there yet?
in Biomarkers in medicine
Clarke JI
(2016)
Recent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?
in Expert opinion on drug safety
Cobice D
(2013)
Mass Spectrometry Imaging for Dissecting Steroid Intracrinology within Target Tissues
in Analytical Chemistry
Cobice D
(2015)
Future technology insight: mass spectrometry imaging as a tool in drug research and development MS imaging for future drug development
in British Journal of Pharmacology
Cobice DF
(2016)
Spatial Localization and Quantitation of Androgens in Mouse Testis by Mass Spectrometry Imaging.
in Analytical chemistry
Cobice DF
(2018)
Quantification of 11ß-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
in Biochemical pharmacology
Currie I
(2019)
ABO-incompatible renal transplantation
in The Lancet
Dear JW
(2018)
Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies.
in The lancet. Gastroenterology & hepatology
Denver N
(2019)
Derivatization enhances analysis of estrogens and their bioactive metabolites in human plasma by liquid chromatography tandem mass spectrometry.
in Analytica chimica acta
Denver N
(2019)
Data for analysis of catechol estrogen metabolites in human plasma by liquid chromatography tandem mass spectrometry.
in Data in brief
| Description | Anne Rowling Clinic (MND project) |
| Amount | £150,000 (GBP) |
| Organisation | Anne Rowling Regenerative Neurology Clinic |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 08/2018 |
| Description | BBSRC Alert 17 (Mass spec) |
| Amount | £722,150 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2018 |
| End | 04/2019 |
| Description | BioQuarter Innovation Competition Winner - Development of a Hepatic Vascular Cathetar CiC1 |
| Amount | £15,000 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 04/2015 |
| Description | CATACURE ICT Policy Support Programme |
| Amount | € 2,700,000 (EUR) |
| Funding ID | 6210885 |
| Organisation | European Commission |
| Department | Competitiveness and Innovation Framework Programme (CIP) |
| Sector | Public |
| Country | Belgium |
| Start | |
| Description | Cariometabolic Health Disease |
| Amount | $10,000 (CAD) |
| Organisation | Fonds de la recherche Québec, Santé (FRQ-S) |
| Sector | Public |
| Country | Canada |
| Start | 03/2019 |
| End | 08/2019 |
| Description | Chief Scientist Office - Catalytic Grant (Mass Spec) |
| Amount | £34,000 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 04/2019 |
| Description | CiC 20012 (steriods) |
| Amount | £14,000 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2023 |
| Description | CiC 2012 ((fibre optic) |
| Amount | £108,000 (GBP) |
| Organisation | Heriot-Watt University |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 10/2017 |
| Description | CiC 2012 (Steroids) |
| Amount | £104,000 (GBP) |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 09/2021 |
| Description | CiC 2012 (fetal diagnostic) |
| Amount | £108,000 (GBP) |
| Organisation | Medical Research Scotland |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 09/2019 |
| Description | CiC 2012 (fetal diagnostic) |
| Amount | £250,000 (GBP) |
| Organisation | Chief Scientist Office |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2016 |
| End | 03/2019 |
| Description | CiC 2012 (fetal diagnostic) |
| Amount | £49,000 (GBP) |
| Organisation | Carnegie Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 09/2018 |
| Description | CiC 2012 (fetal diagnostic) |
| Amount | € 2,500 (EUR) |
| Organisation | German Academic Exchange Service (DAAD) |
| Sector | Academic/University |
| Country | United States |
| Start | 05/2017 |
| End | 06/2020 |
| Description | CiC 2012 (fetal diagnostic) |
| Amount | € 2,500 (EUR) |
| Organisation | German Academic Exchange Service (DAAD) |
| Sector | Academic/University |
| Country | United States |
| Start | 05/2017 |
| End | 06/2020 |
| Description | CiC 2012 (hepatic vascular catheter) |
| Amount | £40,000 (GBP) |
| Organisation | NHS Scotland |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2017 |
| Description | CiC 2012 (micro BRT) |
| Amount | £108,000 (GBP) |
| Organisation | Medical Research Scotland |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 09/2024 |
| Description | CiC 2012 (personalised voices) |
| Amount | £40,000 (GBP) |
| Organisation | Digital Health Institute (DHI) |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 04/2018 |
| Description | CiC A device for label free purification of viable cells for therapy |
| Amount | £50,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | CiC TissueStik |
| Amount | £370,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 12/2016 |
| End | 09/2019 |
| Description | CiC personalised voices for patients with MND |
| Amount | £127,000 (GBP) |
| Organisation | Motor Neurone Disease Association (MND) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | CiC2012 (Steriods) |
| Amount | £2,000 (GBP) |
| Organisation | British Mass Spectrometry Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2017 |
| Description | CiC2012 (Steroids) WT-ISSF2 funding |
| Amount | £44,000 (GBP) |
| Funding ID | X00000294 |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Institutional Strategic Support Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 05/2026 |
| Description | Clinical Research Career Development Fellowship (mirPOC) |
| Amount | £472,987 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Company contribution - Catanostics CiC1 |
| Amount | € 1,300,000 (EUR) |
| Organisation | European Commission |
| Sector | Public |
| Country | European Union (EU) |
| Start | |
| Description | EPSRC - FetaSAFE CiC 1 |
| Amount | £1,300,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2022 |
| Description | GSK CASE PhD Studentship - Developing Mass Spec Imaging CiC1 |
| Amount | £120,000 (GBP) |
| Organisation | GlaxoSmithKline (GSK) |
| Sector | Private |
| Country | Global |
| Start | |
| Description | Industry studentship Johnson Matthey (mircoBRT CIC1) |
| Amount | £116,900 (GBP) |
| Organisation | Johnson Matthey |
| Sector | Private |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2022 |
| Description | Institutional Strategic Support Fund (micro-BRT) |
| Amount | £30,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 07/2017 |
| Description | Institutional Translational Partnership Award (iTPA) Mass Spec project |
| Amount | £20,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 04/2019 |
| Description | Kidney Research UK (mirPOC) |
| Amount | £124,482 (GBP) |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2019 |
| Description | Kidney Research UK - Developing Mass Spec Imaging CiC1 |
| Amount | £63,000 (GBP) |
| Organisation | Kidney Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2020 |
| Description | Michael Smith Foreign Study Supplement (Mass spec) |
| Amount | $6,000 (CAD) |
| Organisation | Michael Smith Foundation for Health Research |
| Sector | Charity/Non Profit |
| Country | Canada |
| Start | 03/2018 |
| End | 09/2018 |
| Description | Moray Trust - for label free purification project CIC1 |
| Amount | £5,000 (GBP) |
| Organisation | Moray Council |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2017 |
| End | 03/2018 |
| Description | Multiplicom funding (Fetasafe) |
| Amount | £10,000 (GBP) |
| Organisation | Multiplicom N.V. |
| Sector | Private |
| Country | Belgium |
| Start | |
| Description | Multiuser Equipment Grant (Steroids) |
| Amount | £850,000 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Bloomsbury Centre |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2017 |
| Description | NHS Research Scotland Career Fellow - Development of a Hepatic Vascular Cathetar CiC1 |
| Amount | £125,000 (GBP) |
| Organisation | NHS Research Scotland |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 03/2017 |
| Description | PhD Scholarship Precision Medicine |
| Amount | £90,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2019 |
| End | 11/2023 |
| Description | PhD based collaboration with Axis Shield - Mircro BRT - CiC 1 |
| Amount | £120,000 (GBP) |
| Organisation | Axis-Shield |
| Sector | Private |
| Country | United Kingdom |
| Start | |
| Description | Phase II High Growth Spin Out |
| Amount | £400,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | PledPharma AB (mirPOC) |
| Amount | £600,000 (GBP) |
| Organisation | Pledpharma AB |
| Sector | Private |
| Country | Sweden |
| Start | 09/2016 |
| End | 01/2018 |
| Description | RSE Enterprise Fellowship |
| Amount | £65,070 (GBP) |
| Organisation | Royal Society of Edinburgh (RSE) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 09/2020 |
| Description | Rosetree Trust Interdisciplinary Prize - mirPOC CiC1 |
| Amount | £250,000 (GBP) |
| Organisation | Rosetrees Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2017 |
| End | 09/2019 |
| Description | Scottish Enterprise High Growth Spin out - FetaSAFE CiC1 |
| Amount | £174,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 08/2017 |
| End | 08/2018 |
| Description | Scottish Government Clinical Evaluation - Personlised voices for MND CiC 1 |
| Amount | £200,000 (GBP) |
| Organisation | Government of Scotland |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 03/2017 |
| Description | Tech Seed Award |
| Amount | £10,000 (GBP) |
| Organisation | Scottish Universities Life Sciences Alliance |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Tech Seed Award |
| Amount | £10,000 (GBP) |
| Organisation | Scottish Universities Life Sciences Alliance |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | |
| Description | Travel Award - Mass Spec project |
| Amount | £800 (GBP) |
| Organisation | British Heart Foundation (BHF) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 09/2018 |
| Description | UKRMP funding - mirPOC - CiC1 |
| Amount | £60,000 (GBP) |
| Organisation | UK Regenerative Medicine Platform |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 10/2015 |
| Description | UoE Inspire, Launch, Grow, Emerging Staff Innovation Award |
| Amount | £1,500 (GBP) |
| Organisation | University of Edinburgh |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2019 |
| End | 06/2020 |
| Description | iCURE funding |
| Amount | £35,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 10/2018 |
| Description | iCure |
| Amount | £210,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2019 |
| Title | CiC A device for label free purification of viable cells for therapy |
| Description | Viable and non-viable cells can also be separated by manipulating their movement in non-uniform electric fields (dielectrophoresis, DEP). This is because, when cells die, their size, plasma-membrane capacitance and ionic porosity change, resulting in changes in the electric field frequencies at which the dielectric properties of the cells exactly match those of the surrounding medium (the so-called DEP crossover frequency or Fxo). By using microelectrodes energised with AC voltages in a defined range of frequencies, distinct Fxos can be established for viable, as compared with non-viable, cells. For example, viable cells typically exhibit a dynamic distribution of DEP Fxos ranging from 50-250 kHz while non-viable cells progress from the upper value of this range beyond 400 kHz as apoptosis progresses1. Such differences in DEP responses can be used to sort cells with high efficiency. Indeed, different cell types of similar size (namely myoblasts and fibroblasts) can be efficiently sorted in this way (to 98% purity at sorting rates of around 2x105 cells per hour) because of differences in their plasma membrane capacitance2. Since differences in DEP responses between viable and non-viable cells are more substantial, we anticipate that increased flow rates can be used to sort viable from non-viable cells more rapidly and that, in combination with 1g sedimentation prior to DEP sorting, rates of viable-cell purification of 106-109 cells per hour can be achieved. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | Investigator has completed a stage 1 H2020 application which could be relevant feedback since, if successful it will extend what we learned about DEP during the CiC (and without the CiC we wouldn't have made the application!). I am leading the application on behalf of UEDIN and the consortium is called CRYOREV (16 partners, a mixture of academic and commercial institutions) and the call is Tools and technologies for advanced therapies PHC-16-2015. The project is entitled Automated revival and monitoring of cryopreserved cells for regenerative therapies, with a DEP cytometer being developed to be used on the monitoring side (one of the work packages). If successful it will provide funding of almost 6 million Euros Dielectrophoresis has the potential to be applied to all types of cell for assessment of viability - for example for pancreatic islet viability analysis. Determination of islet viability prior to transplantation is critical but current techniques are sub-optimal. Based on findings from this CiC project, funding was secured from the EPSRC to investigate translating this technology to pancreatic islet viability testing alongside use of a novel technique for pancreatic islet isolation. The EPSRC project is a collaboration between The Universities of Edinburgh, Newcastle and Heriot-Watt. We also secured a small equipment grant from the Moray Endowment fund to purchase specialised equipment for the latter part of the CiC project. |
| Title | CiC MicroBRT |
| Description | A reagent was developed that can stabilise and extract bacterial RNA from whole blood. A microfluidic device was developed that could process this whole blood in this reagent to prepare samples suitable for bacterial RNA analysis. |
| Type Of Material | Technology assay or reagent |
| Provided To Others? | No |
| Impact | This method is suitable for use in a determination of bacterial RNA in a point of care device that should be able to rapidly report on the early outcome of antibiotic therapy. |
| Description | Aquila Biomedical (Tissuestik) |
| Organisation | Aquila BioMedical |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Tissuestik service was incorporated into Aquila BioMedical suite of services |
| Collaborator Contribution | Aquila recognised the value of this service and incorporated into their business |
| Impact | This service supports the company who have increased their turnover and staff numbers and the company was acquired by Concept Life Sciences in 2017. |
| Start Year | 2014 |
| Description | Arrotek Medical Devices (Hepatic Vascular Catheter) |
| Organisation | Arrotek Medical Limited |
| Country | Ireland |
| Sector | Private |
| PI Contribution | Idea was presented to the company |
| Collaborator Contribution | The project utilised cadaveric testing initially to confirm that the balloon design had potential applicability. Key strength was brought to the project by Arrotek, a balloon design, prototyping and manufacturing company based in Ireland. Arrotek were able to develop iterations rapidly and had a strong understanding of biomedical product development. Having developed a working example, preclinical studies were carried out at UMC Utrecht. This is a first class vascular interventional facility. Fully supported with dedicated theatre staff and interventional radiology, the functional characteristics of the catheter were assessed in vivo and recorded with digital stills, video and angiography. |
| Impact | This product has not developed further due to licensing and patent issues - mainly lack of funding for patents at Univ of Edinburgh and lack of commercial interest from external sources to take this product to market. |
| Start Year | 2013 |
| Description | Catanostics CiC 1 |
| Organisation | Seafield and Cullen Medical Group |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Data and IP |
| Collaborator Contribution | Expertise, Commercial help |
| Impact | Company are applying for a SMART Award in 2017. Outcome to be recorded. |
| Start Year | 2013 |
| Description | CiC Catanostics |
| Organisation | Heriot-Watt University |
| Department | Chemistry |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Catanostics EU & HWU has obtained support entitled 'CATACURE' The total project is €2.7M and has 5 partners across Europe; Sweden and Denmark (opthalmic hospitals), Denmark (optical filters), UK (Edinburgh Biosciences - cataract monitoring is becoming a major part of EBS business), Germany (instrument manufacture). These SMEs have themselves have committed €1.4M cash investment which took a lot of negotiation! Bal Dhillon will Chair the Steering group for this project, keeping a UoE hand in it. The project will deliver several prototype instruments that will provide the appropriate laser illumination for therapy for trials in the opthalmic hospitals and Asia. This ought to be a strong output for the CiC award. |
| Collaborator Contribution | These SMEs have themselves have committed €1.4M cash |
| Impact | Multi-disciplinary academic medical and industrial product development project. |
| Start Year | 2013 |
| Description | CiC EPDD 002 CATANOSTICS |
| Organisation | Edinburgh Instruments Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | we are building the device |
| Collaborator Contribution | partner is providing very valuable hardware |
| Impact | Project complete all miles met. |
| Start Year | 2013 |
| Description | CiC fetaSAFE |
| Organisation | Perkin Elmer |
| Country | United States |
| Sector | Private |
| PI Contribution | We have developed a system for the sample concentration and purification of fetal DNA from maternal blood |
| Collaborator Contribution | Perkin Elmer hare developing tests in this arena and are interested in techniques that can increase the opportunity for low fetal DNA samples to be suitable for assay |
| Impact | materials are being provided by partner for evaluation in the device to bench mark to current technology |
| Start Year | 2015 |
| Description | CiC fetaSAFE |
| Organisation | Sequenom |
| Country | United States |
| Sector | Private |
| PI Contribution | The fetaSAFE team have developed a sample processing device for improving the success rate and potentially lowering the cost barriers to analysis of fetal DNA in maternal circulation. |
| Collaborator Contribution | Sequenom are the world leaders in fetal DNA testing and are engaged in advising and providing bench marking samples for evaluation in the microfluidics technology. |
| Impact | test data not available yet |
| Start Year | 2016 |
| Description | CiC1 - Micro-BRT |
| Organisation | Mercia Technologies PLC |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Applied and presented the opportunity to the company |
| Collaborator Contribution | Applied and presented the opportunity to the company |
| Impact | Mercia has noted an expression of interest to fund this project, which is building a company proposition around Point of Care monitoring for anti-microbial therapy. Potential £50k for Pathfinder award. |
| Start Year | 2018 |
| Description | Destina (mirPOC) |
| Organisation | DestiNA Genomics Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Developed new assay with Destina (UoE spin out). UoE provided science. |
| Collaborator Contribution | Destina providing commercial advice and assistance with assay development |
| Impact | No outputs to report |
| Start Year | 2013 |
| Description | Industry partners, Waters, sponsored Androgens conference 2018 (mass spec) |
| Organisation | Waters Corporation |
| Department | Waters Corporation Centre of Mass Spectrometry Excellence |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | We collaborated with Waters Corp on a CASE studentship application which unfortunately was unsuccessful. We are reapplying in 2019. |
| Collaborator Contribution | Waters Corp agreed to be on of the main sponsors for the Androgens 2018 conference held in Edinburgh which had an international reach. |
| Impact | This conference took place in Edinburgh on 3rd to 5th September 2018, and featured an update on cutting-edge science and provided an excellent opportunity for the research community to foster further collaboration. Plenary lectures by leading experts covered a wide range of exciting research. T |
| Start Year | 2018 |
| Description | MicroBRT CiC |
| Organisation | Axis-Shield |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The MicroBRT project seeks to identify the micro RNA signature from treatment of bacterial pathogens by antibiotics and organise the purification of the analyte using a microfluidic system. |
| Collaborator Contribution | Designing and developing the microfluidic sample processing system. |
| Impact | The partners provided considerable input to the Target Product Profile and the final milestone of the CiC. Discussions are on going regarding next stage of development. A student ship has been initiated on the background science. |
| Start Year | 2016 |
| Description | Multiplicom collaboration (Fetasafe) |
| Organisation | Multiplicom N.V. |
| Country | Belgium |
| Sector | Private |
| PI Contribution | PhD role |
| Collaborator Contribution | Multiplicom provided £10k cash to support the PhD role. |
| Impact | PhD completion |
| Start Year | 2013 |
| Description | Platts and Nisbet - Hepatic Vascular Catheter CIC1 |
| Organisation | Platts & Nisbett Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Provide medical device specifications for prototype and final version - the Currie Clamp |
| Collaborator Contribution | Expertise to made the medical device prototype - the Currie Clamp |
| Impact | Medical device is being used in the Royal Infirmary of Edinburgh. This device prolongs the life of the liver during transplantation. Design protection is being discussed to enable the device for general use in surgical community. |
| Start Year | 2016 |
| Title | TISSUE MANIPULATION DEVICE |
| Description | The present invention relates to methods and devices for use in tissue manipulation, particularly to devices for use in preparation of tissue samples for histological or pathological analysis. Embodiments of the invention relate to devices which are adapted to manipulate tissue samples without coming into physical contact with the tissue samples, thereby avoiding issues of cross-contamination. This can be achieved by coating the tip of the devices with a tissue medium which is used to indirectly manipulate the tissue sample, and then release the sample by melting the tissue medium. |
| IP Reference | WO2015015228 |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | Initiated significant discussions with leading companies |
| Title | UV-Vis fluorescence diagnostics of cataract |
| Description | an instrument using a 315nm-LED and interference filter provides a safe light for detection of cataracts based on modification of the non tryptophan 430nm band generating an optical excitation 310-320nm range. This will provide early detection of cataracts and a quantitative measure of change by deterioration or therapy. |
| IP Reference | GB1323130.3 |
| Protection | Patent application published |
| Year Protection Granted | |
| Licensed | No |
| Impact | The EUR2.7M grant |
| Title | microRNA biomarkers of drug-induced liver injury |
| Description | microRNA biomarkers of drug-induced liver injury |
| IP Reference | GB1512219.5 |
| Protection | Patent application published |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | supporting development |
| Title | CiC EPDD 001 Fibre optic surgical device enabling targeted drug delivery to the posterior eye |
| Description | The product is designed to provide a device that can direct a laser system for reducing the thickness of the sclera at the back of the eye sufficiently for drugs to permeate into the back of the eye. Final milestone ex-vivo demonstration of viable surgical scheme and proof of concept in terms of enhanced drug transport through sclera. The prototype device can deliver a 1-2mm2 array of portals of 100-200um depth that allows increased penetration of large molecule agents. |
| Type | Therapeutic Intervention - Surgery |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2014 |
| Development Status | Under active development/distribution |
| Impact | We are actively seeking further funding and company spinout options. |
| Title | CiC EPDD 002 CATANOSTICS |
| Description | An Instrument for the Early Diagnosis of Cataracts. The product is designed to replace the slit detector with an monitoring of Trytophan Fluorescence using LED for both diagnosis and as a research tool enabling the assessment in trials of pharmaceutical interventions (e.g. N- Acetyl Carnosine as published) as well as the femtosecond laser potential therapy pathway. Final milestone involves building a research prototype machine. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | too early in project. Supporting grant application. |
| Title | CiC EPDD 003 Developing Mass Spectrometric Imaging of Estrogens in Hormone Sensitive Tumours of the Breast. |
| Description | The product will be a compound suitable for facilitating the analytical detection of estrogens in tissue samples. Final milestone will demonstrate FTICR-MS can detect reproducibly androgens and estrogens in breast tumour tissue with RSD<20% and a signal to noise for quantitation >3 and the result can be reported as a quantitative outcome suitable for diagnosis and clinical trials. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | too early in CiC |
| Title | CiC EPDD 004 fetaSAFE - Microfluidic concentration of circulating foetal nucleic acids from maternal blood. |
| Description | The product will be a sample preparation micro fluidic device that will allow rapid separation and concentration of foetal DNA suitable for non-invasive prenatal diagnosis of foetal disease and treatment needs such as for rhesus factor incompatibility. Final milestone will demonstrate if enough cffDNA can be concentrated from maternal blood to make this process useful for NIPD in the first trimester of pregnancy. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | Too early in CiC. worth noting that following an oral presentation considerable interest has been generated and discussions with two key companies have been initiated. |
| Title | CiC EPDD 005 Delivering personalised voices for patients with MND. |
| Description | The product will be system suitable for professional speech therapist to build a personalised voice using any residual patient voice and sampling the voice bank. Final milestones all achieved the voice banking tools consists of - SpeechRecorder (iPhone/iPad) - Easy-to-use speech recording apps using specially designed texts. - Voice Cloning Toolkit (Mac) - Mac software for building speech synthesizers from recorded audio files - SpeakUnique (iPhone/iPad) - Communication apps for patients who want to use their own voices - SAPI5 (Windows) - Text-to-speech engine that can use patient's voices on Windows-based AAC devices such as Tobii or DynaVox. All the above tools have been evaluated and validated by clinicians, speech therapists, and patients and have been iteratively refined many times. As planned, our clinicians and speech therapists have successfully recorded, built and delivered two patient's voices without asking IT researchers or teams. The first patient's voice have been delivered using iPad mini. The second patient's voice have been delivered using SAPI5. |
| Type | Management of Diseases and Conditions |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | We are currently evaluating the potential to establish a company to control the process of manufacture distribution and license. |
| Title | CiC EPDD 006 A Device for Label-Free Purification of Viable Cells for Therapy. |
| Description | The product will be the operative component in a device that separates cells prior to their administration to patients (or other uses) to eliminate dead cells with inhibitory, toxic and proinflammatory properties. Final milestone will deliver a design with potential to be CE marked, manufactured to GMP and works when sterilized that can robustly remove dead cells with the same levels of proficiency (minimally 90% as proficient) as the prototype with at least two cell types with retention of sterility throughout sorting process. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | Early in CiC |
| Title | CiC EPDD 007 Microsystems for the monitoring of Bacterial Response to Therapy. |
| Description | The product will deliver isolation and lysis of bacteria in a microfluidic system with the same response pattern as conventional micro RNA analysis reporting on suitability on antibiotic therapy choice for incorporation into an established analyser. Final milestone will deliver a comprehensive head to head comparison of known biomarkers of bacterial response, coordinated with potential commercial partner. |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | early in CiC |
| Title | CiC EPDD 008 Tissuestik |
| Description | The product already at initial prototype, is a non-contact device for handling histopathology samples that reduces the risk of sample cross-contamination and patient misdiagnosis. Final milestone will deliver data comparing macro, micro and molecular contamination against the current gold standard suitable for publication. It has been demonstrated in a blinded trial to remove cross contamination that occurs within 10 manipulations with current optimal process. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Refinement. Non-clinical |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | The development of this product has help a company to be formed TissuePlex Ltd that is developing a range of improved devices for histology. The team have obtained a TSB grant to develop a water bath product. These innovations will improve processing for current histology and significantly remove the opportunity for error with the evolving field of molecular histology. |
| Title | CiC EPDD 009 Development of a hepatic vascular catheter to improve outcomes during liver transplantation. |
| Description | The product will assist difficult transplants (when cirrhosis is present) when separating the liver form the cava is even more taxing and dangerous and may add several hours to an operation which already takes between 6-10 hours. Reducing the risk of catastrophic bleeding and need for upwards of 40 units of blood, additional clotting factors and a prolonged stay in intensive care would be expected for those patients who survive (£1000 per day in ITU). Final milestone will deliver a device fully evaluated in a large animal model. The first prototype has been evaluated ex vivo and in vivo evaluations are due to take place as soon as the license is secured and the surgical training is complete. |
| Type | Therapeutic Intervention - Medical Devices |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | The Investigator has received an award from the CSO to provide one day per week to focus on innovation. His next product idea won the local innovation competition and was kick-started with the £15,000 prize. |
| Title | CiC EPDD 010 A portable integrated device for organ recovery from donors after circulatory death under normothermic conditions. |
| Description | The product is a portable oxygenation system that would support with a portable extracorporeal membrane oxygenation ECMO for organ recovery from donors after circulatory death is performed. Fewer organs are recovered compared to brain-dead donors (1.7 vs 3.2 organs/donor) and transplantation is associated with more complications. Final milestone will deliver a product will be tested in a head to head comparison with the current equipment used in clinicalractice and will be equivalent capabilities but portable. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | early in CiC |
| Title | CiC EPDD 011 mirPOC - detection of miRNAs indicating drug-induced liver injury at point-of-care. |
| Description | The final product will be an EIS-based assay that has potential to integrate with the Mölnlycke Health Care-Scotland (MHC-S) handset within 1 hour within 10% of PCR fold change. Results clearly distinguish disease (paracetamol-induced liver injury) from control (paracetamol overdose without any injury). Final milestone will deliver a Test can distinguish healthy from diseased by measuring miR-122 levels in 500 clinical samples. Difference in signal >10 fold. Lower limit of the 95% CI >3 fold. Initial deliverables of limit of detection and specificity have been achieved |
| Type | Diagnostic Tool - Non-Imaging |
| Current Stage Of Development | Initial development |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | Establishing a strong working relationship with local company Mölnlycke Health Care-Scotland |
| Title | Currie Clamp - Hepatic Vascular Cathetar CIC1 |
| Description | The 'Currie Clamp' was developed as the original CiC device, hepatic vascular catheter, was more complex to handle in use than expected and technical concerns would prevent direct use in humans. The final version of the Currie Clamp was made by a company in Sheffield, Platts and NISBET, from Sheffield Steel. It is CE marked and is in use in the Royal Infirmary. Discussions have started on design protection so it can be made available to the surgical community. |
| Type | Support Tool - For Medical Intervention |
| Current Stage Of Development | Small-scale adoption |
| Year Development Stage Completed | 2017 |
| Development Status | Under active development/distribution |
| Impact | The Currie Clamp lengthens the life of the liver during transplantation. |
| Description | Clinical Pilot Study - CiC1 MND |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Study participants or study members |
| Results and Impact | Funding from Scottish Government in April 2016 for 12 months £200k, set up a clinical pilot to test the application of our voicebanking technology offered within the NHS. Under this exciting development, speech and language therapists have been trained to use the voicebanking technology and the pilot will assess its application as part of routine clinical care. Initially the pilot is being rolled out in the Lothian, Forth Valley and Greater Glasgow and Clyde health boards, with rural areas covered under the remit of the Scottish Centre of Technology for the Communication Impaired (SCTCI). People with communication impairments who are eligible will be invited to take part by their local speech and language therapists. The pilot will include the collection of both qualitative and quantitative data. |
| Year(s) Of Engagement Activity | 2016 |